Does pharma need to get cracking on Instagram? New features could be the trigger

Tracy Staton Instagram's latest updates could help pharma companies get more out of using the social app. Longer videos, for instance, give more room for drugmakers to comply with ...

Novartis reshuffles its $9B R&D operation to save $1B a year

Damian Garde Swiss pharma giant Novartis is changing up its massive R&D organization in hopes of squeezing out some savings while betting big on new medicines. FierceBiotech News

UPDATED: OncoMed hits the brakes on PhII pancreatic cancer trial, shares plummet

John Carroll OncoMed slammed the brakes on a Phase II study of the cancer stem cell drug tarextumab, citing worsening response rates in the drug arm for pancreatic cancer, with red ...

Yes, Gilead put superhigh prices on hep C drugs, but what can you do? Senators ask

Eric Palmer After 18 months spent slicing and dicing 20,000 pages of Gilead Sciences documents and emails, a Senate investigation concluded that the drugmaker put very high price tags ...

Amgen’s Repatha wins first PCSK9 OK in Japan

Carly Helfand Amgen and the Sanofi and Regeneron team have been duking it out with their PCSK9 meds in the U.S., racing to ink payer deals in an effort to get ahead. But now, Amgen ...

Actelion CEO dismisses talk of Basilea buyout bid

Nick Paul Taylor Actelion CEO Jean-Paul Clozel has dismissed the possibility of making a bid to buy Basilea Pharmaceutica. The comment quashed speculation that Actelion and Basilea ...

Wockhardt spanked again by FDA as agency ticks off violations at new sterile injectables plant

Eric Palmer Wockhardt saw a new plant that will make sterile injectable drugs as its best shot at restoring a U.S. business devastated by FDA product bans. But the Indian ...

Celgene chief Bob Hugin ponders a new era for neurodegeneration R&D

John Carroll SAN FRANCISCO–During a luncheon meeting with reporters at a hotel near a bustling Union Square, Celgene CEO Bob Hugin–soon to be the executive chairman as Mark ...

NeuroVive takes a 10% stake in partner Isomerase

Damian Garde Swedish drug developer NeuroVive Pharmaceutical is cozying up to R&D partner Isomerase Therapeutics, buying a stake in the company as the two move together ...

Kodiak bags a $34M B round for retinal R&D

Damian Garde Ophthalmology biotech Kodiak Sciences raised $ 34 million in Series B financing to speed up its pipeline of ocular therapies. FierceBiotech News

Insect in Baxter saline solution prompts recall

Carly Helfand Baxter has already faced some hurdles supplying saline solution, in October recalling nearly 140,000 bags of sodium chloride on mold worries. Now, it's recalling ...

Novartis provides $170M to kick off Surface Oncology partnership

John Carroll Fledgling Cambridge, MA-based startup Surface Oncology has pulled off its first Big Pharma deal, grabbing $ 170 million in near-term milestones, an upfront and research ...
Page 1 of 9812345...102030...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS